File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine

TitleSeroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine
Authors
KeywordsInfluenza virus A H1N1
Seroprevalence
2009 H1N1 influenza
Antibody titer
Immunogenicity
Issue Date2011
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
Citation
Plos One, 2011, v. 6 n. 11 How to Cite?
Abstract
Background: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local healthcare workers had received the vaccine by February 2010. Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine (Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination inhibition (HI) and viral neutralization (VN) assays. Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval (CI): 44%-63%) had antibody titer ≥1:40 by HI and 42% (95% CI: 33%-52%) had antibody titer ≥1:40 by VN. The proportion of HCWs with antibody titer ≥1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer ≥1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007-08 seasonal influenza vaccine (odds ratio: 0.43; 95% CI: 0.19-1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not statistically significant. Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in HCWs. © 2011 Zhou et al.
Persistent Identifierhttp://hdl.handle.net/10722/143772
ISSN
2013 Impact Factor: 3.534
2013 SCImago Journal Rankings: 1.724
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong University Grants CommitteeAoE/M-12/06
MedImmune Inc.
Roche
Funding Information:

This work has received financial support from the Area of Excellence Scheme of the Hong Kong University Grants Committee (grant no. AoE/M-12/06). The funding body was not involved in the collection, analysis, and interpretation of data, the writing of the article, or the decision to submit it for publication.

References
Grants

 

Author Affiliations
  1. Hong Kong Hospital Authority
  2. The University of Hong Kong
  3. HKU-Pasteur Research Centre
DC FieldValueLanguage
dc.contributor.authorZhou, Yen_HK
dc.contributor.authorNg, DMWen_HK
dc.contributor.authorSeto, WHen_HK
dc.contributor.authorIp, DKMen_HK
dc.contributor.authorKwok, HKHen_HK
dc.contributor.authorMa, ESKen_HK
dc.contributor.authorNg, Sen_HK
dc.contributor.authorLau, LLHen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorCowling, BJen_HK
dc.date.accessioned2011-12-21T08:54:26Z-
dc.date.available2011-12-21T08:54:26Z-
dc.date.issued2011en_HK
dc.identifier.citationPlos One, 2011, v. 6 n. 11en_HK
dc.identifier.issn1932-6203en_HK
dc.identifier.urihttp://hdl.handle.net/10722/143772-
dc.description.abstractBackground: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local healthcare workers had received the vaccine by February 2010. Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in Hong Kong in February-March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine (Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination inhibition (HI) and viral neutralization (VN) assays. Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval (CI): 44%-63%) had antibody titer ≥1:40 by HI and 42% (95% CI: 33%-52%) had antibody titer ≥1:40 by VN. The proportion of HCWs with antibody titer ≥1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer ≥1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007-08 seasonal influenza vaccine (odds ratio: 0.43; 95% CI: 0.19-1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not statistically significant. Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in HCWs. © 2011 Zhou et al.en_HK
dc.languageengen_US
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.actionen_HK
dc.relation.ispartofPLoS ONEen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectInfluenza virus A H1N1-
dc.subjectSeroprevalence-
dc.subject2009 H1N1 influenza-
dc.subjectAntibody titer-
dc.subjectImmunogenicity-
dc.titleSeroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccineen_HK
dc.typeArticleen_HK
dc.identifier.emailIp, DKM: dkmip@hku.hken_HK
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_HK
dc.identifier.emailCowling, BJ: bcowling@hku.hken_HK
dc.identifier.authorityIp, DKM=rp00256en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.identifier.authorityCowling, BJ=rp01326en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1371/journal.pone.0027169en_HK
dc.identifier.pmid22102878-
dc.identifier.pmcidPMC3213124-
dc.identifier.scopuseid_2-s2.0-80755159561en_HK
dc.identifier.hkuros197999en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80755159561&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue11en_HK
dc.identifier.spagee27169en_US
dc.identifier.epagee27169en_US
dc.identifier.isiWOS:000297348800017-
dc.publisher.placeUnited Statesen_HK
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza-
dc.identifier.scopusauthoridZhou, Y=54410057000en_HK
dc.identifier.scopusauthoridNg, DMW=36497437400en_HK
dc.identifier.scopusauthoridSeto, WH=7005799377en_HK
dc.identifier.scopusauthoridIp, DKM=35117701600en_HK
dc.identifier.scopusauthoridKwok, HKH=26644099900en_HK
dc.identifier.scopusauthoridMa, ESK=24725277400en_HK
dc.identifier.scopusauthoridNg, S=34977173400en_HK
dc.identifier.scopusauthoridLau, LLH=36010688600en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridCowling, BJ=8644765500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats